Eli Lilly and Company $LLY Shares Sold by WealthShield Partners LLC

WealthShield Partners LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,235 shares of the company’s stock after selling 52 shares during the quarter. WealthShield Partners LLC’s holdings in Eli Lilly and Company were worth $2,522,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter worth about $35,000. TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $55,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LLY shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Guggenheim reissued a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $999.28.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,024.67 on Friday. The company has a 50-day simple moving average of $826.89 and a 200 day simple moving average of $780.87. The company has a market capitalization of $968.70 billion, a P/E ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the company earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.